RESOURCES

Development of small macrocyclic kinase inhibitors

Abzena, Alira Health and Oncodesign launch DRIVE-Biologics to support access to specialist services

Abzena x Alira Health x Oncodesign: unveil unique integrated solution with specialist services, from biologics discovery to clinical & commercial manufacturing

Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity

Published in Science Advances: the preclinical development program of exoASO-STAT6, a novel, engineered #exosome precision medicine candidate for the treatment of macrophage-rich tumors.

SEngine Precision Medicine & Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment

Read all the details of the collaboration agreement for R&D of a new personalized cancer treatment for aggressive and untreatable tumors.

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients

Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.

Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections

SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.

Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases

Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.

[EN] How Rodent and NHP Models Support COVID-19 Treatment Development

Learn how to select the most appropriate COVID-19 animal model for preclinical studies in this webinar

[EN] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program

Learn how the DRIVE-MRT solution enables the rationalization, design & optimization of targeted & effective radiopharmaceuticals against specific cancers.

ONCODESIGN strengthens the intellectual property of ODS 101 in treating inflammatory bowel disease

Protection of RIPK2 inhibitors resulting from Nanocyclix® technology with patents granted on the main international markets: Europe, United States, Japan and Eurasia

Oncodesign: EHDEN Certified SME

EHDEN network will enable transparent & fully reproducible research by standardizing both the health data & the analytical pipeline.

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.